Companies
Iovance
Lifileucel (Amtagvi) — the first approved TIL drug; iCTC mega-plant (Philadelphia) for thousands of patients.
- Country
- United States
FDA approved
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $319 million in cash and cash equivalents as of March 31, 2026 | ir.iovance.com |
| Capacity | currently built to supply TIL products for more than 2,000 patients/year, with expansion underway to supply over 5,000 patients annually | ir.iovance.com · quarterlytics.com · iovance.com · marketscreener.com · pharmaceutical-technology.com · sec.gov |
| Certification | LEED certified (iCTC) | iovance.com · pharmaceutical-technology.com |
| Regulatory approval | U.S. FDA accelerated approval for Amtagvi (lifileucel) for advanced melanoma on February 16, 2024 | ir.iovance.com · sec.gov |
| Production site | Iovance Cell Therapy Center (iCTC) in Philadelphia, Pennsylvania | iovance.com · pharmaceutical-technology.com |
| Revenue | total product revenue of approximately $71 million for the first quarter of 2026 | ir.iovance.com · last10k.com · stocktitan.net |
| Revenue | total revenue of $263.5 million for the full year 2025 | last10k.com · stocktitan.net |
Independent sources: last10k.com · marketscreener.com · pharmaceutical-technology.com · quarterlytics.com · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TIL therapy (tumor-infiltrating lymphocytes) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.